Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts [Yahoo! Finance]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: Yahoo! Finance
in 43 countries — six months ahead of schedule — and Celldex expects a sequence of 2026 readouts led by prurigo nodularis in summer and the Phase III CSU readout in Q4 2026. Durability/disease-modifying signal : Celldex reported up to a 71% complete response at 52 weeks and 41% still complete responders at 76 weeks off drug, with biomarker and PK findings suggesting responses outlast expected drug exposure and raising the possibility of disease modification. Dosing, safety and positioning : Phase III uses loading doses to improve early response with maintenance doses from Phase II and the company expects a similar safety profile (transient neutropenia, mild reversible pigment changes); management targets patients with severe CSU/angioedema and a second-line advanced role, while other programs (CIndU, PN, AD, CDX-622) have near-term data plans. Interested in Celldex Therapeutics, Inc.? Here are five stocks we like better. Celldex Therapeutics (NASDAQ:CLDX) executives highlighte
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Weakness And Strong 1 Year Return [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics (CLDX) had its price target raised by The Goldman Sachs Group, Inc. from $30.00 to $34.00. They now have a "neutral" rating on the stock.MarketBeat
- Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-DiseaseAcquire Media Monitor
- Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-DiseaseGlobeNewswire
CLDX
Earnings
- 2/25/26 - Miss
CLDX
Sec Filings
- 3/10/26 - Form SCHEDULE
- 2/25/26 - Form 10-K
- 2/25/26 - Form 8-K
- CLDX's page on the SEC website